RT Journal Article
SR Electronic
T1 Association between immune-related adverse events and clinical outcomes for head and neck squamous cell carcinoma treated with first-line palliative pembrolizumab monotherapy or in combination with chemotherapy: a national, multi-centre, real-world, retrospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.08.23290541
DO 10.1101/2023.06.08.23290541
A1 Thapa, Alekh
A1 Cowell, Anna
A1 Peters, Adam
A1 James, Allan
A1 Lamb, Carolynn
A1 Grose, Derek
A1 Vohra, Saurabh
A1 Schipani, Stefano
A1 Mactier, Karen
A1 Mackenzie, Joanna
A1 Noble, David J
A1 Srinivasan, Devraj
A1 Laws, Kirsten
A1 Moleron, Rafael
A1 Niblock, Paddy
A1 Soh, Feng Yi
A1 Paterson, Claire
A1 Wilson, Christina
YR 2023
UL http://medrxiv.org/content/early/2023/06/12/2023.06.08.23290541.abstract
AB Objectives To provide real-world performance data and identify clinical factors associated with survival outcomes for patients receiving first-line pembrolizumab-containing treatment for head and neck squamous cell carcinoma (HNSCC) in the palliative setting.Materials and Methods We analysed the electronic records of patients who initiated pembrolizumab-containing treatment between 01/03/2020–30/09/2021. Outcomes included overall survival (OS), progression-free survival (PFS), duration of response (DOR), disease control rate (DCR). Data were compared with the KEYNOTE-048 study and clinical factors were evaluated for association with survival.Results Our cohort included 91 patients (median follow-up 10.8 months). For patients receiving monotherapy (n=76), 12-month and 24-month OS was 45% and 27%, respectively, 12-month PFS was 22%, median DOR was 13.3 months, and DCR was 56.6%. For patients receiving pembrolizumab-chemotherapy (n=15), 12-month OS was 60%, 12-month PFS was 20%, median DOR was 7.3 months and DCR was 60.0%.Experiencing ≥1 irAE (versus no irAEs), of any grade, was associated with favourable OS and PFS for patients receiving monotherapy in both univariable log-rank analysis (median OS 17.4 months versus 8.6 months, respectively, P=0.0033; median PFS 10.9 months versus 3.0 months, respectively, P<0.0001) and multivariable analysis (Cox proportional hazards regression: OS HR: 0.31, P=0.0009; PFS HR: 0.17, P<0.0001).Conclusion Our real-world data, first from a European population, support the KEYNOTE-048 study findings. Additionally, our data is first to show irAEs are associated with better outcomes in this patient group, adding to the growing body of evidence showing irAEs are generally a positive marker of PD-L1 inhibitor response.Competing Interest StatementChristina Wilson reports an honoraria from MSD outwith this study. Rafael Moleron reports advisory boards for MSD and Vasodynamics. All remaining authors report no conflicts of interest.Funding StatementClaire Paterson is supported by NHS Research Scotland (NRS) senior fellowship, Beatson Cancer Charity and CRUK RadNet Glasgow. David Noble is supported by an NHS Research Scotland (NRS) senior fellowship, and the Jamie King Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The local National Health Service Information Governance team at the Beatson West of Scotland Cancer Centre waived ethical approval for this work on the grounds that the study collected anonymised health service clinical practice data only.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.